NASDAQ:CRME - Cardiome Pharma Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cardiome Pharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range N/A52-Week Range N/AVolume90,444 shsAverage Volume135,322 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRME Previous Symbol CUSIPN/A CIK1036141 Webhttp://www.cardiome.com/ Phone604-677-6905Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Receive CRME News and Ratings via Email Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter. Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions What is Cardiome Pharma's stock symbol? Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME." How were Cardiome Pharma's earnings last quarter? Cardiome Pharma Co. (NASDAQ:CRME) issued its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to the consensus estimate of $7.34 million. View Cardiome Pharma's Earnings History. Has Cardiome Pharma been receiving favorable news coverage? Media stories about CRME stock have trended somewhat negative on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cardiome Pharma earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Cardiome Pharma. Who are some of Cardiome Pharma's key competitors? Some companies that are related to Cardiome Pharma include Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Immune Therapeutics (IMUN), Mereo BioPharma Group (MREO), Myrexis (MYRX) and NeuroVive Pharmaceutical (NEVPF). What other stocks do shareholders of Cardiome Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer LP Unit (ET), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Strategic Value Fund (CLM), Cornerstone Total Return Fund (CRF), SunCoke Energy Partners (SXCP), Martin Midstream Partners (MMLP), Navios Maritime Midstream Partners (NAP), Government Properties Income Trust (GOV) and Arlington Asset Investment (AI). Who are Cardiome Pharma's key executives? Cardiome Pharma's management team includes the folowing people: Dr. William L. Hunter, Pres, CEO & Director (Age 55)Ms. Sheila M. Grant MBA, Chief Operating OfficerMr. David D. McMasters, Gen. Counsel (Age 59)Mr. Hugues Sachot, Chief Commercial OfficerMr. Justin A. Renz, Chief Financial Officer (Age 46) What is Cardiome Pharma's official website? The official website for Cardiome Pharma is http://www.cardiome.com/. How can I contact Cardiome Pharma? Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected] MarketBeat Community Rating for Cardiome Pharma (NASDAQ CRME)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 553MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: FinTech
